Mr. Speaker, with regard to question (a), while recipients of Health Canada’s substance use and addictions program, or SUAP, funding are required to report back to Health Canada using standard performance metrics, this level of detail falls outside of what is collected by the department.
With regard to question (b), there are a number of prescription drugs approved by Health Canada that provinces, territories and authorized health practitioners can access for both medication-assisted drug treatment programs and safer supply pilot projects. Information on the specific brands of medications dispensed to safer supply clients is often recorded at the pharmacy level only, not by the programs themselves. Health Canada does not formally collect information on the manufacturers for the medications provided through funded safer supply pilot projects.
With regard to question (c), as of December 2022, the expenditures are as follows: $593,109 in 2018-19; $1,484,049 in 2019-20; $11,906,315 in 2020-21; $20,219,932 in 2021-22; $34,400,062 in 2022-23; and $9,282,388 in 2023-24.
With regard to question (d), as previously mentioned, information regarding how much each manufacturer is paid each year for the range of substances prescribed falls outside of what is collected by the department.